With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
|Articles|June 10, 2020
FDA Authorizes Real-Time PCR Assay for COVID-19
Author(s)Kevin Kunzmann
ChromaCode now intends to use its own multiplexing technology to help launch a COVID-19 assay later this year. The assay would combine multiple respiratory viruses into a single test in anticipation of the upcoming flu season.
Advertisement
The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to ChromaCode’s HDPCR SARS-CoV-2 Real-Time PCR Assay.
The assay authorization grants the company utility for the device’s purpose of detecting SARS-CoV-2 from nasopharyngeal swab specimens from patients suspected by their healthcare providers of having contracted
ChromaCode now intends to use its own multiplexing technology to help launch a COVID-19 assay later this year. The assay would combine multiple respiratory viruses into a single test in anticipation of the upcoming flu season.
The company’s assay platform runs on standard qPCR instruments with no required hardware/software changes, and provides a US Centers for Disease Control and Prevention (CDC) assay consolidated into a single reaction well—allowing labs to run 1000-plus samples per qPCR instrument over a 24/7 testing period.
"Customers continue to experience extraordinary increases in testing volume; our ability to enable labs to process thousands of samples in one day using existing laboratory equipment means they can rapidly scale testing to meet high demands," Greg Gosch, ChromaCode's Co-founder, president and chief executive officer, said in a
As such, the company is guaranteeing ongoing supply for customers who sign an agreement, Gosch said.
Advertisement
Related to this article
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
Advertisement
Advertisement
Trending on Contagion Live
1
FAQ: Pneumonic Plague
2
Ebola Deaths Top 4,100 as Kenya Confirms First Imported Bundibugyo Case
3
Russian Lab Worker Dies in Suspected Pneumonic Plague Case
4
VAX-31 Meets Primary Endpoints in Phase 3 Pneumococcal Vaccine Study
5